Paul Kelly

Dr. Paul Kelly is a Founding Partner of OneVentures and Head of Healthcare at OneVentures. He serves on the investment committee of OneVentures' three main Funds, chairing the Healthcare Fund III Investment Committee, and leads the healthcare and biotechnology practice across the firm. Paul is currently Chair on the Boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of BiVACOR, Clinical Genomics and Prota Therapeutics.

Paul is an Australian physician and serial biotechnology entrepreneur with over 30 years' experience in developing and commercializing biomedical innovations in the United States, Europe, United Kingdom and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, with a record of achievement in transforming ideas, technologies and products into sustainable successful businesses and delivering strong returns for shareholders and investors as a founder and CEO, before co founding OneVentures in 2009. Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specializing in endocrinology. Paul is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Hons), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians, and serves on the Board of Directors of the Garvan Institute of Medical Research, one of Australia’s leading medical research institutes.